Journal of Experimental Orthopaedics

Table 4 Changes of bone turnover markers and BMD in the naïve and switch groups after 6 and 12 months of treatment

From: Effects of denosumab on bone mineral density and bone turnover markers in rheumatoid arthritis patients switching from bisphosphonates

	Naïve group (n = 25)					Switch group (n = 11)
	Baseline	6 months	P	12 months	P	Baseline	6 months	P	12 months	P
Total-PINP (ng/ml)	73.4 ± 5.5	30.6 ± 3.6	<0.05	32.5 ± 3.5	<0.05	36.8 ± 5.1	25.6 ± 3.8	n.s	29.9 ± 5.7	n.s
TRACP-5b (mU/dl)	426.2 ± 31.3	244.8 ± 27.6	<0.05	250.2 ± 22.4	<0.05	320.7 ± 21.0	278.4 ± 47.9	n.s	276.6 ± 40.0	n.s
ucOC (ng/ml)	4.1 ± 0.5	1.6 ± 0.2	<0.05	1.5 ± 0.2	<0.05	2.3 ± 0.6	1.1 ± 0.3	<0.05	1.4 ± 0.4	n.s
Spine BMD (g/cm²)	0.83 ± 0.04	0.88 ± 0.05	<0.05	0.89 ± 0.05	<0.05	0.85 ± 0.04	0.88 ± 0.04	<0.05	0.89 ± 0.04	<0.05
FN BMD (g/cm²)	0.60 ± 0.01	0.62 ± 0.01	<0.05	0.62 ± 0.01	<0.05	0.57 ± 0.03	0.59 ± 0.03	<0.05	0.59 ± 0.02	n.s
TH BMD (g/cm²)	0.62 ± 0.01	0.63 ± 0.02	n.s	0.64 ± 0.02	<0.05	0.62 ± 0.03	0.63 ± 0.03	n.s	0.63 ± 0.03	n.s

Data are presented as means ± standard deviation (SD), Naïve group: treatment-naïve group; Switch group: transitioning from bisphosphonate group; BMD: bone mineral density; total-PINP: total-procollagen type I N-terminal propeptide; TRACP-5b: tartrate-resistant acid phosphatase-5b; ucOC: undercarboxylated osteocalcin; FN: femoral neck; TH: total hip. P values from Wilcoxon’s rank sum test for the change from baseline within each treatment group

Back to article page